Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum
Authors:
Open Access
- 17 November 2023
- journal article
- research article
- Published by Elsevier in Leukemia Research Reports
- Vol. 20, 100395
Abstract
No abstract availableKeywords
Funding Information
- Kurozumi Medical Foundation
This publication has 15 references indexed in Scilit:
- APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myelomaNature Communications, 2015
- Relationship between initial clinical presentation and the molecular cytogenetic classification of myelomaLeukemia, 2013
- Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cellsBlood, 2013
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogeneticsBlood, 2012
- A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialLeukemia, 2011
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)Journal of Clinical Oncology, 2010
- Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapyBlood, 2005
- Genetics and Cytogenetics of Multiple MyelomaCancer Research, 2004
- A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains anIGH/MMSET fusion transcriptBlood, 2003
- Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variantsBlood, 2003